1347720-73-3

Upstream product

• 183322-16-9 3,4-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 861106-91-4 (2-bromo-6-nitro-phenyl)-methanol 
• 861106-90-3 2-bromo-6-nitrobenzyl acetate 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 179688-29-0 6,7-bis-(2-methoxyethoxy)-4(3H)quinazolinone 
• 179688-26-7 2-nitro-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 3943-89-3 Ethyl protocatechuate 
• 861106-92-5 (2-amino-6-bromophenyl)methanol 
• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 

Relevant academic research and scientific papers

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF

At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.